JY
CADX

Jeff Yass’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

Jeff Yass’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-206,656
Closed -$1.87M – 9963
2013
Q4 		$1.87M Buy
206,656
+129,707
+169% +$937K ﹤0.01% 4394
2013
Q3 		$486K Buy
76,949
+62,858
+446% +$400K ﹤0.01% 6473
2013
Q2 		$96K Buy
+14,091
New +$98.2K ﹤0.01% 7804

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Jeff Yass's CADX Position: Q1 2014 in Review

Jeff Yass sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 206,656 shares — an estimated $1.87M sold.

Jeff Yass first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $1.87M in Q4 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

  • Jeff Yass reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
  • Jeff Yass sold 206,656 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $1.87M.
  • Jeff Yass first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
  • Jeff Yass's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $1.87M in Q4 2013.
  • 3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on Susquehanna International Group's 13F filing for Q1 2014, filed 14 May 2014.